Related Experiment Video
Updated: Apr 25, 2026
07:37
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
1.4K
Pharmacogenetics in rheumatoid arthritis
Deepali Sen1, Jisna R Paul, Prabha Ranganathan
1Division of Rheumatology, Department of Medicine, Washington University School of Medicine, 660 S. Euclid Avenue, Campus Box 8045, St. Louis, MO, 63110, USA.
Methods in Molecular Biology (Clifton, N.J.)
|August 25, 2014
Summary
Pharmacogenetics, the study of how genes affect drug response, shows promise for rheumatoid arthritis (RA) treatment. Understanding genetic variations could personalize disease-modifying antirheumatic drug (DMARD) therapy for better RA outcomes.
Area of Science:
- Rheumatology
- Pharmacogenetics
- Immunology
Background:
- Rheumatoid arthritis (RA) is a systemic inflammatory condition causing significant joint damage, morbidity, and mortality.
- Disease-modifying antirheumatic drugs (DMARDs) are the primary treatment for RA, managing symptoms and slowing disease progression.
- Biologic agents, a newer class of DMARDs, offer treatment options but exhibit variable patient responses in efficacy and toxicity.
Purpose of the Study:
- To review the current literature on the pharmacogenetics of traditional and biologic DMARDs in rheumatoid arthritis.
- To explore the potential of pharmacogenetics in predicting individual patient responses to RA therapies.
- To highlight how pharmacogenetics may enable personalized drug therapy for RA patients in the future.
Main Methods:
- Literature review of published studies on pharmacogenetics of DMARDs in rheumatoid arthritis.
- Analysis of genetic factors influencing patient response to traditional and biologic DMARDs.
- Synthesis of current knowledge regarding pharmacogenetic predictors of efficacy and toxicity.
Main Results:
- Significant variability exists in patient responses to current DMARDs, including biologic agents.
- Existing literature on the pharmacogenetics of RA treatments is highlighted.
- Pharmacogenetic approaches are emerging as potential tools for predicting drug response.
Conclusions:
- Pharmacogenetics holds promise for individualizing drug therapy in rheumatoid arthritis.
- Further research is needed to establish reliable pharmacogenetic markers for DMARD selection.
- Personalized medicine approaches using pharmacogenetics could optimize RA treatment outcomes.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
156
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
156
01:29Pharmacogenomics: Identification of New Drug Targets
119
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
119
01:11Genome-wide Association Studies-GWAS
12.3K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
12.3K
01:27Pharmacogenetics of Drug Metabolism: Overview
191
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
191
01:29Pharmacogenetics and Pharmacogenomics: Overview
241
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
241
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
80
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
80